Clinical Trial of Rimegepant for Trigeminal Neuralgia Enrolls First Participant

The first patient has been enrolled in a double-blind placebo-controlled clinical trial (NCT03941834) to assess rimegepant (Biohaven Pharmaceuticals, New Haven, CT)—a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist—for treatment of trigeminal neuralgia refractory to medical treatment. The primary outcome measure is the change in a participant's average Numeric Pain Rating Scale between the 2 treatment phases of the study. 

"CGRP is an important mechanistic target that has been implicated in a variety of diseases,” said Robert Croop, MD, chief development officer—neurology, Biohaven. “Emerging evidence suggests that aberrant release of CGRP from the trigeminal ganglion plays a critical role in the development of pain syndromes such as trigeminal neuralgia. We believe this study involves the first oral CGRP receptor antagonist being studied for use as a potential treatment of trigeminal neuralgia and extends our CGRP clinical research beyond migraine." 

Blood Biomarkers May Help to Predict Length of Recovery Time from  Concussion

Previous News Article

FDA Approves Eculizumab for Treatment of Neuromyelitis Optica Spectrum Disorders

Next News Article
This Month's Issue
The New CPT Codes for Video-EEG

Marc Nuwer, MD, PhD

Neuromuscular Notes: Rhabdomyolysis

Farah El-Sadi, MD; and Aaron Izenberg, MD, FRCPC